- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Clopidogrel/Acetylsalicylic acid Teva has been withdrawn at the request of the marketing-authorisation holder.
Clopidogrel / Acetylsalicylic acid Teva : EPAR - Summary for the public
English (EN) (551.84 KB - PDF)
български (BG) (640.29 KB - PDF)
español (ES) (551.49 KB - PDF)
čeština (CS) (619.76 KB - PDF)
dansk (DA) (553.34 KB - PDF)
Deutsch (DE) (552.85 KB - PDF)
ελληνικά (EL) (644.13 KB - PDF)
français (FR) (552.72 KB - PDF)
hrvatski (HR) (572.63 KB - PDF)
italiano (IT) (572.75 KB - PDF)
latviešu valoda (LV) (616.07 KB - PDF)
lietuvių kalba (LT) (579.55 KB - PDF)
magyar (HU) (611.27 KB - PDF)
Malti (MT) (621.63 KB - PDF)
Nederlands (NL) (549.73 KB - PDF)
polski (PL) (618.45 KB - PDF)
português (PT) (551.97 KB - PDF)
română (RO) (577.7 KB - PDF)
slovenčina (SK) (616.92 KB - PDF)
slovenščina (SL) (608.26 KB - PDF)
Suomi (FI) (548.85 KB - PDF)
svenska (SV) (550.28 KB - PDF)
Clopidogrel / Acetylsalicylic acid Teva : EPAR - Risk-management-plan summary
English (EN) (554.72 KB - PDF)
Product information
Clopidogrel / Acetylsalicylic acid Teva : EPAR - Product Information
English (EN) (1.15 MB - PDF)
български (BG) (2.74 MB - PDF)
español (ES) (1.22 MB - PDF)
čeština (CS) (2.14 MB - PDF)
dansk (DA) (1.17 MB - PDF)
Deutsch (DE) (1.21 MB - PDF)
eesti keel (ET) (1.15 MB - PDF)
ελληνικά (EL) (2.84 MB - PDF)
français (FR) (1.23 MB - PDF)
hrvatski (HR) (1.26 MB - PDF)
íslenska (IS) (1.2 MB - PDF)
italiano (IT) (1.41 MB - PDF)
latviešu valoda (LV) (2.16 MB - PDF)
lietuvių kalba (LT) (1.27 MB - PDF)
magyar (HU) (2.22 MB - PDF)
Malti (MT) (2.24 MB - PDF)
Nederlands (NL) (1.19 MB - PDF)
norsk (NO) (1.16 MB - PDF)
polski (PL) (2.29 MB - PDF)
português (PT) (1.2 MB - PDF)
română (RO) (1.26 MB - PDF)
slovenčina (SK) (2.24 MB - PDF)
slovenščina (SL) (2.09 MB - PDF)
Suomi (FI) (1.31 MB - PDF)
svenska (SV) (1.16 MB - PDF)
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Clopidogrel / Acetylsalicylic acid Teva : EPAR - All Authorised presentations
English (EN) (465.95 KB - PDF)
български (BG) (559.88 KB - PDF)
español (ES) (466.06 KB - PDF)
čeština (CS) (525.42 KB - PDF)
dansk (DA) (466.53 KB - PDF)
Deutsch (DE) (467.23 KB - PDF)
eesti keel (ET) (470.64 KB - PDF)
ελληνικά (EL) (538.45 KB - PDF)
français (FR) (466.03 KB - PDF)
hrvatski (HR) (514.42 KB - PDF)
íslenska (IS) (465.5 KB - PDF)
italiano (IT) (467.22 KB - PDF)
latviešu valoda (LV) (528.72 KB - PDF)
lietuvių kalba (LT) (517.37 KB - PDF)
magyar (HU) (522.9 KB - PDF)
Malti (MT) (559.02 KB - PDF)
Nederlands (NL) (465.99 KB - PDF)
norsk (NO) (465.81 KB - PDF)
polski (PL) (498.85 KB - PDF)
português (PT) (466.07 KB - PDF)
română (RO) (513.43 KB - PDF)
slovenčina (SK) (542.59 KB - PDF)
slovenščina (SL) (525.83 KB - PDF)
Suomi (FI) (467.09 KB - PDF)
svenska (SV) (466.42 KB - PDF)
Product details
- Name of medicine
- Clopidogrel/Acetylsalicylic acid Teva
- Active substance
- clopidogrel
- acetylsalicylic acid
- International non-proprietary name (INN) or common name
- clopidogrel
- acetylsalicylic acid
- Therapeutic area (MeSH)
- Acute Coronary Syndrome
- Myocardial Infarction
- Anatomical therapeutic chemical (ATC) code
- B01AC30
Pharmacotherapeutic group
combinationsTherapeutic indication
Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed?dose combination medicinal product for continuation of therapy in:
- Non?ST segment elevation acute coronary syndrome (unstable angina or non?Q?wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention
ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy
Authorisation details
- EMA product number
- EMEA/H/C/002272
- Marketing authorisation holder
- Teva Pharma B.V.
Swensweg 5
2031GA Haarlem
The Netherlands - Opinion adopted
- 26/06/2014
- Marketing authorisation issued
- 01/09/2014
- Revision
- 1
Assessment history
Clopidogrel/Acetylsalicylic acid Teva : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (523.44 KB - PDF)
Clopidogrel / Acetylsalicylic acid Teva : EPAR - Public assessment report
English (EN) (1.5 MB - PDF)
CHMP summary of positive opinion for Clopidogrel / Acetylsalicylic acid Teva
English (EN) (563.03 KB - PDF)
News on Clopidogrel/Acetylsalicylic acid Teva
More information on Clopidogrel/Acetylsalicylic acid Teva
Public statement on Clopidogrel/Acetylsalicylic acid Teva: Withdrawal of the marketing authorisation in the European Union
English (EN) (65.62 KB - PDF)